Floatz Rating
BB64/100
Confidence
Indicative
Sponsor
Ohio State University Comprehensive Cancer Center
Modality
Small molecule
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
64High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05412875CT.gov Pilot Trial of E Cigarettes in Pts Diagnosed With Cancer of the Head, Neck, and Lung | — | Withdrawn | — | — | — |
NCT00790569CT.gov Varenicline or Nicotine Patch and Nicotine Gum in Helping Smokers in a Methadone Treatment Program Stop Smoking | — | Completed | — | — | — |
NCT00365508CT.gov Counseling and Nicotine Replacement Therapy in Helping Adult Smokers Quit Smoking | — | Completed | — | — | — |
NCT00310141CT.gov Computer-Assisted Counseling in Helping African American Smokers Stop Smoking | — | Completed | — | — | — |
NCT00033592CT.gov Comparison of Nicotine Inhaler and/or Bupropion in Helping People to Stop Smoking and Prevent the Recurrence of Smoking | — | Completed | — | — | — |
NCT00032084CT.gov S0002 - A Program to Quit Smoking With or Without Bupropion in Treating Patients With Stage I or II Non-Small Cell Lung Cancer Who Have Undergone Surgery | — | Terminated | — | — | — |
NCT00021138CT.gov Computer-Assisted Scheduling of Nicotine Inhaler Use in Participants Who Plan to Stop Smoking | — | Completed | — | — | — |
NCT00002520CT.gov Physician-Initiated Stop-Smoking Program for Patients Receiving Treatment for Early-Stage Cancer | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
65High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Lung Cancer
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Nicotine (this asset) | Ohio State University Comprehensive Cancer Center | Approved | BB · 64 |
| Cis-Diamminedichloroplatinum Ii | University of Vermont | P4 | BB |
| Carboplatin | SystImmune Inc. | P4 | BB |
| Desflurane | Peter MacCallum Cancer Centre, Australia | P4 | BB |
| Etoposide | SystImmune Inc. | P3 | BB |
| Nivolumab | University of Chicago | P4 | BB |
| Propofol | Kaohsiung Medical University Chung-Ho Memorial Hospital | P4 | BB |
| Vinorelbine Ditartrate | Alliance for Clinical Trials in Oncology | P3 | BB |
| Vinblastine | Intensity Therapeutics, Inc. | P3 | BB |
+42 more in the Lung Cancer cohort
Other indications for Nicotine
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Nicotine Dependence | — | P4 | A · 83 |
| Cognitive Disorder | — | P2 | BBB · 73 |
| Schizophrenia | — | P4 | BB · 71 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Nicotine in Lung Cancer. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/nicotine-lung-cancer
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →